| Ytd | -26.43% | |
| 1y | -32.35% |
| Open | 92.25 | Prev Close | 90.74 | Low | 91.77 | High | 94.00 | Mkt Cap | 160.56B |
| Vol | 13.05M | Avg Vol | 13.15M | EPS | 3.57 | P/E | 25.82 | Forward P/E | 15.21 |
| Beta | 0.62 | Short Ratio | 1.84 | Inst. Own | 82.53% | Dividend | 2.52 | Div Yield | 2.78 |
| Ex Div Date | 07-15 | Earning | 07-16 | 50-d Avg | 88.87 | 200-d Avg | 112.01 | 1yr Est | 116.54 |
ABT News
Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics,
Futures are trading lower as we get ready to start the third quarter after a record-setting second q
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top Wall Street analysts changed their outlook on top names. See the latest analyst ratings and cove
Baird analyst David Rescott initiates coverage on Abbott Laboratories (NYSE:ABT) with a Outperfor
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its pre
This relationship between inflation and value stocks' outperformance is often overlooked. Many inves
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysio
https://www.wsj.com/us-news/law/the-baby-formula-probe-produced-a-pile-of-evidence-then-the-doj-drop
The U.S. Justice Department closed a criminal probe into Abbott Laboratories over how it managed
WASHINGTON—The Justice Department spent years investigating Abbott Laboratories ABT 0.94%increase; u
During times of market turmoil, investors cycle back into defensive, dividend-focused names like Abb
DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy.
ABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter
ALZpath's pTau217 antibody is among the most clinically validated for detecting Alzheimer's
Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and
Wall Street marched near records as the Strait of Hormuz reopens and oil sinks. Yet 20 large caps, f
Abbott must face a class-action lawsuit over claims its PediaSure drinks are clinically proven to he
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes ma